Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance

Key Points

• This research aims to develop a bispecific, dual-payload antibody-drug conjugate (ADC) to tackle tumor heterogeneity and resistance.
• Discusses the design strategy for ADCs
• Explores the concept of utilizing tumor adaptation
• Focuses on the bispecific approach to target different tumor characteristics
• Presents a novel strategy for ADC design against difficult-to-treat cancers
• Highlights potential improvements in overcoming payload limitations
• Suggests enhanced efficacy in treating heterogeneous tumors

Abstract